Insmed initiated with a Buy at Jefferies

Jefferies initiated coverage of Insmed (INSM) with a Buy rating and $105 price target The company’s “first-in-disease status”, strong clinical profile, and enthusiasm among key opinion leaders should assure a rapid launch for its brensocatib drub, which is a “potential megablockbuster” bronchiectasis treatment, the analyst tells investors in a research note. Insmed’s commercial asset Arikayce is also likely to expand to first-line MAC lung disease, Jefferies added.